Search

Your search keyword '"V. Tsimihodimos"' showing total 159 results

Search Constraints

Start Over You searched for: Author "V. Tsimihodimos" Remove constraint Author: "V. Tsimihodimos"
159 results on '"V. Tsimihodimos"'

Search Results

51. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.

52. Short-term Glycemic Variability and Its Association With Macrovascular and Microvascular Complications in Patients With Diabetes.

53. Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study.

54. The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia.

55. The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum: will gliflozins have a different fate than statins?

56. Effect of Clinical and Laboratory Parameters on HDL Particle Composition.

57. Effect of the first and second COVID-19 associated lockdown on the metabolic control of patients with type 2 diabetes in Greece.

58. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.

59. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.

60. A Study of the Metabolic Pathways Affected by Gestational Diabetes Mellitus: Comparison with Type 2 Diabetes.

61. Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes.

62. Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).

63. Progressive, Qualitative, and Quantitative Alterations in HDL Lipidome from Healthy Subjects to Patients with Prediabetes and Type 2 Diabetes.

64. Serum Uric Acid Levels and Cardiometabolic Profile in Middle-Aged, Treatment-Naïve Hypertensive Patients.

65. The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology.

66. Altered RBC membrane lipidome: A possible etiopathogenic link for the microvascular impairment in Type 2 diabetes.

67. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?

68. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.

69. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.

70. Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients.

72. Early Signs of Atherogenic Features in the HDL Lipidomes of Normolipidemic Patients Newly Diagnosed with Type 2 Diabetes.

73. Lipidomics in non-alcoholic fatty liver disease.

74. The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk.

75. Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study.

76. No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study.

77. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.

78. Apolipoprotein CIII and diabetes. Is there a link?

79. SGLT1 inhibition: Pros and cons.

80. SGLT2 inhibitors and the kidney: Effects and mechanisms.

81. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids.

82. Diagnostic lipid changes in patients with visceral leishmaniasis.

83. Effects of evolving lipid-lowering drugs on carbohydrate metabolism.

84. Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories.

85. Effects of incretin-based therapies on renal function.

86. SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms.

87. Incretins and Lipid Metabolism.

88. PCSK9 and carbohydrate metabolism: A double-edged sword.

89. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences.

90. NMR-Based Lipid Profiling of High Density Lipoprotein Particles in Healthy Subjects with Low, Normal, and Elevated HDL-Cholesterol.

91. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.

92. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.

93. Antidiabetic Drugs and the Kidney.

94. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.

95. Pathophysiology of Diabetic Dyslipidaemia.

97. Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece.

99. Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece.

100. Summarizing the FIELD study: lessons from a 'negative' trial.

Catalog

Books, media, physical & digital resources